PathCo Abstract

Pathogen Co-infection: HIV-1, Tuberculosis, Malaria and hepatitis C virus


Acquired immune deficiency syndrome (AIDS), tuberculosis (TB) and malaria are the primary infectious diseases causing death world wide. TB is responsible for a third to a half of human immunodeficiency virus type 1 (HIV-1)-associated deaths, particularly in sub Saharan Africa and South East Asia. Malaria is widely spread in tropical Africa and accounts for approximately 800,000 deaths every year. In addition to these pathogens, 170 million people are infected with hepatitis C virus (HCV), which may lead to chronic liver disease, liver cirrhosis and hepatocellular carcinoma. Because of shared routes of transmission, HCV co-infection is recognized as a major cause of morbidity and mortality among HIV-1 infected persons.

Effective drugs to control these infectious agents are limited and treatment is made even more challenging by the development of drug-resistant pathogens. Importantly, co-infection with one or more of these pathogens limits the efficacy of available drugs. The epidemiological and clinical features of co-infected subjects is well documented, however, there is a paucity of basic scientific studies addressing the molecular interaction(s) between these pathogens. Variant pathogen strains are known to influence infection and disease outcome, however, the underlying mechanism(s) are unknown.

PathCo consortium propose that pathogen evasion and dysregulation of host immune responses play a key role in co-infection associated morbidity. We will test this hypothesis by developing in vitro and ex vivo co-infection model systems to study pathogen interactions. The specific objectives of this project are to improve our understanding of pathogen co-infection effect(s) on host innate and adaptive immune responses and to develop new approaches to dissect pathogen interactions: ranging from the genesis of fluorescent labelled viruses to state-of-the-art tissue explant culture systems and novel humanised mouse models. Translational studies of infected subjects will define pathogen-specific effects on host immune responses and consequences for disease progression. It is imperative that such interactions are elucidated before evaluating new prophylactic or therapeutic strategies in co-infected individuals.

PathCo Project Focus

The PathCo project brings together powerful multidisciplinary technologies that will improve our understanding of the complex interactions between infectious agents and the host immune response that will significantly improve the management of co-infection associated disease.

Recent developments in each of the disease disciplines enable the design of model systems that support pathogen co-infection, highlighting the timeliness of PathCo’s mission to study the biological and immunological consequences of co-infection(s).

Ultimately such knowledge will be instrumental in the rational design of new therapies and vaccines to control HIV-1, TB, malaria and HCV. In parallel to generating and utilizing new tools to understand the basic biology of pathogen co-interactions the PathCo consortium members will develop novel anti-microbials for translational research.  The PathCo project will identify new targets for therapy and vaccine design, whilst validating known agents for their ability to block pathogen transmission and to target antigen or anti-pathogen components to dendritic cells (DCs).

The PathCo consortium consists of ten beneficiaries from five EU countries (Netherlands, UK, France, Germany and Italy) and one beneficiary from non-EU countries (South Africa).

PathCo team is a well-balanced team of immunologists, virologists, clinicians, statisticians, epidemiologists with expertise in HIV/AIDS, TB, malaria and hepatitis C infection research and has the most appropriate scientific and technical background as well as the animal models and instrumentation required to fulfill the goals of this project and to succeed in its mission. PathCo beneficiaries will have access to well-characterised established cohorts of co-infected patients from different geographical locations. Given the widespread global nature of the pathogens under study it is imperative that we are not biased in our selection of patients.



July 2017
Annual Scientific Meeting
13-14 July 2017 Cape Town, South Africa:

pdf Agenda
pdf List of Participants

archive News archive

PathCo Newsletter

pdf newsletter october 2015

PathCo Brochure

pdf download the
brochure in PDF

Project info

Acronym: PathCo
EC Contribution: € 5.909.690
Duration: 60 months
Starting date: 01/11/2012
Instrument: Collaborative project

Bill Paxton
The University of Liverpool Department of Clinical Infection, Microbiology and Immunology Institute of Infection and Global Health
The Ronald Ross Building West Derby Street 8 Liverpool L69 7BE United Kingdom



This project is supported through Coordination Theme 1 (Health) of the European Community's FP7. Grant agreement number

Last update: 07/12/2017